Scarica l'app Stockscreener
27.81
0.94%
0.26
Dopo l'orario di chiusura:
27.80
-0.010
-0.04%
Bright Minds Biosciences Inc Borsa (DRUG) Ultime notizie
6,600 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Acquired by Jane Street Group LLC - Defense World
40,379 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Purchased by Millennium Management LLC - Defense World
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Buy” from Analysts - Defense World
Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Bright Minds Showcases Revolutionary CNS Drug Portfolio at Major Jefferies Healthcare Conference - Stock Titan
What is Chardan Capital’s Forecast for DRUG FY2025 Earnings? - Defense World
HC Wainwright Issues Pessimistic Outlook for DRUG Earnings - Defense World
Chardan Capital Reiterates “Buy” Rating for Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Bright Minds Biosciences (DRUG) Receives Consistent 'Buy' Rating from Chardan Capital | DRUG Stock News - GuruFocus
Bright Minds (DRUG) Schedules Virtual R&D Day to Discuss Epileps - GuruFocus
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 - The Manila Times
Top Neurologists Reveal Latest Absence Epilepsy Breakthrough: Bright Minds Showcases Phase 2 Trial Progress - Stock Titan
FY2025 Earnings Forecast for DRUG Issued By Chardan Capital - Defense World
How To Trade (DRUG) - news.stocktradersdaily.com
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded at Cantor Fitzgerald - Defense World
Bright Minds Biosciences (DRUG) to Release Earnings on Wednesday - Defense World
TD Cowen Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy Recommendation - Nasdaq
Bright Minds stock rating initiated with Buy at TD Cowen - Investing.com Australia
TD Cowen Initiates Coverage on Bright Minds Biosciences (DRUG) w - GuruFocus
Bright Minds stock rating initiated with Buy at TD Cowen By Investing.com - Investing.com Nigeria
Bright Minds Biosciences Says BMB-101 Eliminated Drop Attacks in Mouse Model of Epilepsy - marketscreener.com
Bright Minds (DRUG) Reports Promising Results in Epilepsy Research | DRUG Stock News - GuruFocus
Bright Minds reports BMB-101 eliminates drop attacks in mice By Investing.com - Investing.com Nigeria
Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 - The Manila Times
Bright Minds (DRUG) Gains 'Buy' Rating from TD Cowen Analyst | D - GuruFocus
Brokerages Set Bright Minds Biosciences Inc. (NASDAQ:DRUG) Target Price at $83.25 - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Research Coverage Started at Chardan Capital - Defense World
Chardan Capital Initiates a Buy Rating on Bright Minds Biosciences (DRUG) - The Globe and Mail
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside - Benzinga
(DRUG) On The My Stocks Page - news.stocktradersdaily.com
Chardan Capital Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy Recommendation - Nasdaq
Chardan sets Bright Minds stock Buy rating, $80 target By Investing.com - Investing.com India
Chardan sets Bright Minds stock Buy rating, $80 target - Investing.com
Piper Sandler Reaffirms Their Buy Rating on Bright Minds Biosciences (DRUG) - The Globe and Mail
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study - The Manila Times
Major Epilepsy Breakthrough? Phase 2 Trial Results for Revolutionary Seizure Drug Coming May 20 - Stock Titan
Piper Sandler sets $93 target for Bright Minds Biosciences stock - MSN
Uncover the Best-Performing Canadian Biotech Stocks of 2025 - Investing News Network
When (DRUG) Moves Investors should Listen - news.stocktradersdaily.com
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 (NASDAQ:DRUG) - Seeking Alpha
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Discover the Top 5 Small-Cap Biotech Stocks in 2025 - Investing News Network
(DRUG) Trading Advice - news.stocktradersdaily.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Significant Decrease in Short Interest - Defense World
DRUG FY2025 EPS Estimate Decreased by Cantor Fitzgerald - The AM Reporter
Cantor Fitzgerald Has Weak Forecast for DRUG FY2025 Earnings - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 0.8% – Here’s Why - Defense World
Bright Minds Biosciences Independent Director Nils Bottler Sells 100% Of Holding - simplywall.st
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research - GlobeNewswire
Bright Minds Biosciences Strengthens Epilepsy Focus with New Advisory Board Members - TipRanks
Can These 5 Epilepsy Experts Accelerate Bright Minds' Breakthrough Drug Development? - StockTitan
0.86%
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):